IsomAb secures funds to advance peripheral arterial disease treatment
IsomAb has secured £7.5m in a seed funding round to expedite the development of its lead candidate targeting peripheral arterial disease.
📰 Broadview Ventures News
Broadview Ventures News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Broadview Ventures. Real-time updates on events, politics, business and more.
IsomAb Raises £7.5M in Funding
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
Nottingham Biocity Steve Harper Jackie Turnbull David Bates University Of Nottingham Proof Of Concept Early Stage Fund
Source: finsmes.com
IsomAb builds towards £35m Series A after £7.5m seed round is backed by US money
Biotech company IsomAb Ltd, whose registered office is at St John’s Innovation Centre in Cambridge, has excited investors with its antibody technology. The company has closed a £7.5 million financing to accelerate its lead candidate to treat peripheral arterial disease.
Source: businessweekly.co.uk
IsomAb Announces Close of £7.5 Million Financing to Accelerate Lead Candidate for Treatment of Peripheral Arterial Disease
/PRNewswire/ -- IsomAb Ltd, a UK-based biotechnology company, announced today the closing of a £7.5 million (approximately US$9.4 million) Seed financing...
Source: prnewswire.com
Acesion Pharma announces Nature Medicine publication of clinical results in Atrial Fibrillation
/PRNewswire/ -- Acesion Pharma ("Acesion" or "the Company"), a biotech company pioneering first-in-class novel therapies for atrial fibrillation ("AF"), the...
Acesion Pharma Anders Gaarsdal Holst Novo Holdings Global Bioaccess Fund Nature Medicine Gaarsdal Holst
Source: prnewswire.com
Cardiosense Begins Enrollment in Nationwide Heart Failure Study
/PRNewswire/ -- Cardiosense, a digital health company developing a non-invasive monitoring platform for the early detection of heart disease, recently started...
Source: prnewswire.com
Advanced HF No Obstacle to AF Ablation Success: CASTLE-HTx
This should help eradicate the current somewhat nihilistic approach to managing atrial fibrillation in advanced heart failure, said an expert.
Source: medscape.com
Acesion Pharma Announces Positive Pre-Clinical Data for AP31969
/PRNewswire/ -- Acesion Pharma ("Acesion" or "the Company"), a biotech company pioneering first-in-class novel therapies for atrial fibrillation ("AF"), the...
Anders Gaarsdal Holst Prnewswire Acesion Pharma Acesion Pharma Novo Holdings Gaarsdal Holst Chief Executive Officerof Acesion
Source: prnewswire.com
Acesion Pharma announces positive phase 2 data from Atrial Fibrillation clinical trial
/PRNewswire/ -- Acesion Pharma ("Acesion"), the biotech pioneering first-in-class novel therapies for Atrial Fibrillation ("AF"), the most common cardiac...
A John Camm Acesion Pharma Anders Gaarsdal Holst George University Of London Novo Holdings Atrial Fibrillation
Source: prnewswire.com
Basking Biosciences Presents Positive Clinical Results from Safety and Dose-Escalation Study for Fir
-BB-031, a potential rapid onset, short-acting and reversible thrombolytic, targets von Willebrand Factor, a key structural component of thrombi and driver of blood clotting--Company to initiate a Phase 2 clinical proof-of-concept study of BB-031 in patients with acute ischemic stroke-COLUMBUS, Ohio--(BUSINESS WIRE)...
Source: pharmiweb.com